甲磺酸倍他司汀

甲磺酸倍他司汀用途

Betahistine mesylate 是一种具有口服活性的的组胺 H1 受体 (histamine H1 receptor) 激动剂和 H3 受体 (H3 receptor) 的拮抗剂。Betahistine 可以用于类风湿性关节炎 (RA) 的研究。

甲磺酸倍他司汀名称

[ CAS 号 ]:
54856-23-4

[ 中文名 ]:
甲磺酸倍他司汀

[ 英文名 ]:
Betahistine Mesylate

[中文别名 ]:

[英文别名 ]:

N-Methyl-2-pyridineethanamine Dimethanesulfonate
MFCD00211321
EINECS 259-377-7

甲磺酸倍他司汀生物活性

[ 描述 ]:

[ 相关类别 ]:

信号通路 >> 免疫及炎症 >> 组胺受体

研究领域 >> 炎症/免疫

信号通路 >> G 蛋白偶联受体/G 蛋白 >> 组胺受体

[体外研究]

甲磺酸倍他司汀(0-10μM)可抑制[125I]碘氧自由基与CHO(rH3(445)R)和CHO(hH3(445)R)细胞膜的IC50分别为1.9μM和3.3μM。Ki值分别为1.4μM和2.5μM[2]。甲磺酸倍他司汀(0～10μM)对CHO(rH3(445)R)、CHO(rH3(413)R)和CHO(hH3(445)R)细胞cAMP的形成具有调节作用。低浓度时,甲磺酸倍他司汀表现为明显的反激动剂,并逐渐增强cAMP的形成,EC50值分别为0.1nm、0.05nm和0.3nm。相比之下,在浓度高于10nm时,甲磺酸倍他司汀抑制cAMP的形成,CHO(rH3(445)R)的EC50值为0.1μM,激动剂活性完全[2]。

[体内研究]

甲磺酸倍他司汀(腹腔或口服；0.1-30mg/kg；单次给药)急性给药后,远端甲基组胺(t-MeHA)水平增加,ED50为0.4mg/kg,显示出相反的痛苦。此外,急性口服给药后,雄性Swissmice的t-MeHA水平增加,ED50为2 mg/kg[2]。甲磺酸倍他司汀(口服；1和5 mg/kg；每天3周)可减轻关节炎的严重程度,并降低CIA小鼠足组织中促炎细胞因子的水平[3]。动物模型：胶原诱导关节炎(CIA)DBA/1雄性小鼠模型[3]剂量：1mg/kg；5mg/kg给药：口服；诱导21d后第21天至第42天结果：通过减少关节破坏改善小鼠CIA。

[参考文献]

[1]. Poyurovsky M, et al. The effect of Betahistine mesylate, a histamine H1 receptor agonist/H3 antagonist, on olanzapine-induced weight gain in first-episode schizophrenia patients. Int Clin Psychopharmacol. 2005 Mar;20(2):101-3.

[2]. Gbahou F, et al. Effects of Betahistine mesylate at histamine H3 receptors: mixed inverse agonism/agonism in vitro and partial inverse agonism in vivo.J Pharmacol Exp Ther. 2010 Sep 1;334(3):945-54.

[3]. Tang KT, et al. Betahistine mesylate attenuates murine collagen-induced arthritis by suppressing both inflammatory and Th17 cell responses.Int Immunopharmacol. 2016 Oct;39:236-245

甲磺酸倍他司汀物理化学性质

[ 沸点 ]:
210.9ºC at 760 mmHg

[ 熔点 ]:
112°C

[ 分子式 ]:
C₁₀H₂₀N₂O₆S₂

[ 分子量 ]:
328.406

[ 闪点 ]:
96.7ºC

[ 精确质量 ]:
328.076263

[ PSA ]:
150.42000

[ LogP ]:
2.40400

[ 外观性状 ]:
固体;White to Almost white powder to crystal

[ 储存条件 ]:
通风低温干燥

甲磺酸倍他司汀MSDS

详细MSDS(安全技术说明书)

甲磺酸倍他司汀毒性和生态

CHEMICAL IDENTIFICATION

RTECS NUMBER :: UT2970200

CHEMICAL NAME :: 2-Pyridineethanamine, N-methyl-, dimethanesulfonate

CAS REGISTRY NUMBER :: 54856-23-4

LAST UPDATED :: 198212

DATA ITEMS CITED :: 9

MOLECULAR FORMULA :: C8-H12-N2.2C-H4-O3-S

MOLECULAR WEIGHT :: 328.44

WISWESSER LINE NOTATION :: T6NJ A2M1 &QSW1 2

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 3030 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

REFERENCE :: NIIRDN Drugs in Japan (Ethical Drugs). (Yakugyo Jiho Co., Ltd., Tokyo, Japan) Volume(issue)/page/year: 6,750,1982

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Subcutaneous

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 940 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

REFERENCE :: NIIRDN Drugs in Japan (Ethical Drugs). (Yakugyo Jiho Co., Ltd., Tokyo, Japan) Volume(issue)/page/year: 6,750,1982

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Intravenous

SPECIES OBSERVED :: Rodent - rat

DOSE/DURATION :: 604 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

REFERENCE :: NIIRDN Drugs in Japan (Ethical Drugs). (Yakugyo Jiho Co., Ltd., Tokyo, Japan) Volume(issue)/page/year: 6,750,1982

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 500 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

REFERENCE :: NIIRDN Drugs in Japan (Ethical Drugs). (Yakugyo Jiho Co., Ltd., Tokyo, Japan) Volume(issue)/page/year: 6,750,1982

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Subcutaneous

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 1630 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

REFERENCE :: NIIRDN Drugs in Japan (Ethical Drugs). (Yakugyo Jiho Co., Ltd., Tokyo, Japan) Volume(issue)/page/year: 6,750,1982

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Intravenous

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 505 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

REFERENCE :: NIIRDN Drugs in Japan (Ethical Drugs). (Yakugyo Jiho Co., Ltd., Tokyo, Japan) Volume(issue)/page/year: 6,750,1982

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Rodent - guinea pig

DOSE/DURATION :: 1400 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

REFERENCE :: NIIRDN Drugs in Japan (Ethical Drugs). (Yakugyo Jiho Co., Ltd., Tokyo, Japan) Volume(issue)/page/year: 6,750,1982

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Subcutaneous

SPECIES OBSERVED :: Rodent - guinea pig

DOSE/DURATION :: 120 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

REFERENCE :: NIIRDN Drugs in Japan (Ethical Drugs). (Yakugyo Jiho Co., Ltd., Tokyo, Japan) Volume(issue)/page/year: 6,750,1982

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Intravenous

SPECIES OBSERVED :: Rodent - guinea pig

DOSE/DURATION :: 22900 ug/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

REFERENCE :: NIIRDN Drugs in Japan (Ethical Drugs). (Yakugyo Jiho Co., Ltd., Tokyo, Japan) Volume(issue)/page/year: 6,750,1982

甲磺酸倍他司汀安全信息

[ RTECS号 ]:
UT2970200

[ 海关编码 ]:
2933399090

甲磺酸倍他司汀海关

[ 海关编码 ]: 2933399090

[ 中文概述 ]:
2933399090. 其他结构含非稠合吡啶环的化合物. 增值税率:17.0%. 退税率:13.0%. 监管条件:无. 最惠国关税:6.5%. 普通关税:20.0%

[ 申报要素 ]: 品名, 成分含量, 用途, 乌洛托品请注明外观, 6－己内酰胺请注明外观, 签约日期

[ Summary ]:
2933399090. other compounds containing an unfused pyridine ring (whether or not hydrogenated) in the structure. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0%

甲磺酸倍他司汀文献

Comparison of the therapeutic efficacy of a fixed low-dose combination of cinnarizine and dimenhydrinate with betahistine in vestibular neuritis: a randomized, double-blind, non-inferiority study.

Clin. Drug Investig. 32(6) , 387-99, (2012)

Vestibular neuritis (VN) is a strongly disabling disease of the peripheral vestibular system. Rapid and effective relief of symptoms is important to allow patients to promptly return to normal physica...

Betahistine or Cinnarizine for treatment of Meniere's disease.

Med. Arh. 66(6) , 396-8, (2012)

Meniere's disease is a condition with sudden attacks of vertigo with nausea and vomiting accompanied by loss of hearing and buzzing sensation in the ears, most commonly unilateral. The exact cause of ...

Vestibular rehabilitation with virtual reality in Ménière's disease.

Braz. J. Otorhinolaryngol. 79(3) , 366-74, (2013)

Virtual reality technology can provide a wide range of sensory stimuli to generate conflicts of varying degrees of complexity in a safe environment.To verify the effect of a virtual realitybased balan...

更多文献